Pieter Faber

2.2k total citations
22 papers, 1.6k citations indexed

About

Pieter Faber is a scholar working on Molecular Biology, Oncology and Immunology. According to data from OpenAlex, Pieter Faber has authored 22 papers receiving a total of 1.6k indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Molecular Biology, 7 papers in Oncology and 5 papers in Immunology. Recurrent topics in Pieter Faber's work include Cytokine Signaling Pathways and Interactions (4 papers), Renal cell carcinoma treatment (3 papers) and Epigenetics and DNA Methylation (3 papers). Pieter Faber is often cited by papers focused on Cytokine Signaling Pathways and Interactions (4 papers), Renal cell carcinoma treatment (3 papers) and Epigenetics and DNA Methylation (3 papers). Pieter Faber collaborates with scholars based in United States, Germany and Australia. Pieter Faber's co-authors include Min Pi, John Harrington, Kurt R. Brunden, L. Darryl Quarles, Nancy Wang, Anthony E. Ting, Robert W. Mays, Marcy E. MacDonald, Scott T. Brady and Maureen Young and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Nucleic Acids Research and Journal of Biological Chemistry.

In The Last Decade

Pieter Faber

21 papers receiving 1.6k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Pieter Faber United States 15 1.0k 435 227 200 190 22 1.6k
Kazuhiro Ogi Japan 27 1.4k 1.3× 349 0.8× 612 2.7× 186 0.9× 93 0.5× 74 2.3k
Gilbert-André Keller United States 14 1.0k 1.0× 165 0.4× 200 0.9× 160 0.8× 144 0.8× 17 1.9k
Masao Kishikawa Japan 24 735 0.7× 198 0.5× 190 0.8× 225 1.1× 75 0.4× 88 1.8k
Marella Maroder Italy 24 1.1k 1.1× 127 0.3× 360 1.6× 340 1.7× 330 1.7× 35 1.8k
Katsuhito Takahashi Japan 26 1.2k 1.2× 166 0.4× 159 0.7× 147 0.7× 185 1.0× 61 2.1k
Mary B. Breslin United States 20 553 0.5× 95 0.2× 333 1.5× 109 0.5× 377 2.0× 37 1.3k
Andrea Gashler United States 9 1.6k 1.6× 288 0.7× 244 1.1× 225 1.1× 270 1.4× 9 2.1k
Olive S. Pettengill United States 24 1.1k 1.0× 316 0.7× 758 3.3× 113 0.6× 287 1.5× 63 2.0k
Janice D. Rone United States 18 629 0.6× 237 0.5× 250 1.1× 75 0.4× 173 0.9× 32 1.2k
Henning B. Boldt Denmark 23 833 0.8× 107 0.2× 264 1.2× 215 1.1× 231 1.2× 44 2.2k

Countries citing papers authored by Pieter Faber

Since Specialization
Citations

This map shows the geographic impact of Pieter Faber's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Pieter Faber with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Pieter Faber more than expected).

Fields of papers citing papers by Pieter Faber

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Pieter Faber. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Pieter Faber. The network helps show where Pieter Faber may publish in the future.

Co-authorship network of co-authors of Pieter Faber

This figure shows the co-authorship network connecting the top 25 collaborators of Pieter Faber. A scholar is included among the top collaborators of Pieter Faber based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Pieter Faber. Pieter Faber is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Eckert, Mark A., Shawn Pan, Kyle M. Hernandez, et al.. (2016). Genomics of Ovarian Cancer Progression Reveals Diverse Metastatic Trajectories Including Intraepithelial Metastasis to the Fallopian Tube. Cancer Discovery. 6(12). 1342–1351. 130 indexed citations
2.
Yim, Howard Chi Ho, Die Wang, Christine L. White, et al.. (2016). The kinase activity of PKR represses inflammasome activity. Cell Research. 26(3). 367–379. 32 indexed citations
3.
Bao, Riyue, Pieter Faber, Vytautas P. Bindokas, et al.. (2015). Notch1 Activation or Loss Promotes HPV-Induced Oral Tumorigenesis. Cancer Research. 75(18). 3958–3969. 24 indexed citations
4.
Marotta, Michael, Xiongfong Chen, Takaaki Watanabe, et al.. (2013). Homology-mediated end-capping as a primary step of sister chromatid fusion in the breakage-fusion-bridge cycles. Nucleic Acids Research. 41(21). 9732–9740. 16 indexed citations
5.
Lin, Zhenwu, John P. Hegarty, Wei Yu, et al.. (2012). Identification of Disease-Associated DNA Methylation in B Cells from Crohn’s Disease and Ulcerative Colitis Patients. Digestive Diseases and Sciences. 57(12). 3145–3153. 51 indexed citations
6.
Yu, Wei, Zhenwu Lin, John P. Hegarty, et al.. (2010). Genes regulated by Nkx2-3 in siRNA-mediated knockdown B cells: Implication of endothelin-1 in inflammatory bowel disease. Molecular Genetics and Metabolism. 100(1). 88–95. 13 indexed citations
7.
Lin, Z, John P. Hegarty, Wei Yu, et al.. (2010). Identification of disease-associated DNA methylation in intestinal tissues from patients with inflammatory bowel disease. Clinical Genetics. 80(1). 59–67. 64 indexed citations
8.
Fader, Amanda N., Nabila Rasool, S. A. Vaziri, et al.. (2010). CCL2 expression in primary ovarian carcinoma is correlated with chemotherapy response and survival outcomes.. PubMed. 30(12). 4791–8. 39 indexed citations
9.
Pi, Min, Ling Chen, Minzhao Huang, et al.. (2008). GPRC6A Null Mice Exhibit Osteopenia, Feminization and Metabolic Syndrome. PLoS ONE. 3(12). e3858–e3858. 201 indexed citations
10.
Lane, Brian R., Jianbo Li, Ming Zhou, et al.. (2008). Differential Expression in Clear Cell Renal Cell Carcinoma Identified by Gene Expression Profiling. The Journal of Urology. 181(2). 849–860. 25 indexed citations
11.
Faber, Pieter, S. A. Vaziri, Paul Elson, et al.. (2008). Potential non-synonymous single nucleotide polymorphisms (nsSNPs) associated with toxicity in metastatic clear cell renal cell carcinoma (MCCRCC) patients (pts) treated with sunitinib. Journal of Clinical Oncology. 26(15_suppl). 5009–5009. 5 indexed citations
12.
Faber, Pieter, et al.. (2008). Cisplatin beim Ovarialkarzinom: wieviel und wie lange?. DMW - Deutsche Medizinische Wochenschrift. 110(12). 472–476.
13.
Olencki, Thomas, L. Wood, Lisa Rybicki, et al.. (2007). Gene Modulatory Effects, Pharmacokinetics, and Clinical Tolerance of Interferon-α1b: A Second Member of the Interferon-α Family. Clinical Pharmacology & Therapeutics. 81(3). 354–361. 14 indexed citations
14.
Singh, Arun D., Karen Sisley, Yan Xu, et al.. (2007). Reduced expression of autotaxin predicts survival in uveal melanoma. British Journal of Ophthalmology. 91(10). 1385–1392. 30 indexed citations
15.
Pi, Min, Pieter Faber, Anthony E. Ting, et al.. (2005). Identification of a Novel Extracellular Cation-sensing G-protein-coupled Receptor. Journal of Biological Chemistry. 280(48). 40201–40209. 255 indexed citations
16.
Szebenyi, Györgyi, Gerardo Morfini, Milena Gould, et al.. (2003). Neuropathogenic Forms of Huntingtin and Androgen Receptor Inhibit Fast Axonal Transport. Neuron. 40(1). 41–52. 247 indexed citations
17.
Faber, Pieter. (1998). Huntingtin interacts with a family of WW domain proteins. Human Molecular Genetics. 7(9). 1463–1474. 333 indexed citations
18.
Höffken, K., et al.. (1986). Aminoglutethimide without hydrocortisone in the treatment of postmenopausal patients with advanced breast cancer.. PubMed. 70(10). 1153–7. 14 indexed citations
19.
Göbel, U., Rainer Haas, D. Harms, et al.. (1983). Behandlungsstrategie für nichttestikuläre maligne Keimzelltumoren bei Kindern und Jugendlichen - Konzept der kooperativen Therapiestudie MAKEI 83 der GPO*. Klinische Pädiatrie. 195(3). 201–206. 8 indexed citations
20.
Faber, Pieter & H. J. Jesdinsky. (1979). Adjuvant chemotherapy in breast cancer—a multicenter trial. Cancer Treatment Reviews. 6. 75–78. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Kazuhiro Ogi Breakdown of academic impact, for papers by Gilbert-André Keller Breakdown of academic impact, for papers by Masao Kishikawa Breakdown of academic impact, for papers by Marella Maroder Breakdown of academic impact, for papers by Katsuhito Takahashi Breakdown of academic impact, for papers by Mary B. Breslin Breakdown of academic impact, for papers by Andrea Gashler Breakdown of academic impact, for papers by Olive S. Pettengill Breakdown of academic impact, for papers by Janice D. Rone Breakdown of academic impact, for papers by Henning B. Boldt
Rankless by CCL
2026